Publication: Cutaneous adverse reactions to calcium channel blockers
1
Issued Date
2014-01-01
Resource Type
ISSN
22288694
0125877X
0125877X
Other identifier(s)
2-s2.0-84911869730
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Allergy and Immunology. Vol.32, No.3 (2014), 246-250
Suggested Citation
Papapit Tuchinda, Kanokvalai Kulthanan, Sakunee Khankham, Kowit Jongjarearnprasert, Naruemon Dhana Cutaneous adverse reactions to calcium channel blockers. Asian Pacific Journal of Allergy and Immunology. Vol.32, No.3 (2014), 246-250. doi:10.12932/AP0380.32.3.2014 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/34013
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cutaneous adverse reactions to calcium channel blockers
Other Contributor(s)
Abstract
© 2014, Allergy and Immunology Society of Thailand. All rights reserved. Background: Previous studies have shown that calcium channel blockers can cause cutaneous adverse reactions; however, the amounts of data collected are limited. Recently, there have been new drugs available for which only a few reports have been published with regard to cutaneous adverse reactions.Objective: The purpose of our study was to estimate the rate and to study clinical patterns of cutaneous adverse drug reactions to calcium channel blockers.Methods: Medical records of patients who had cutaneous adverse reactions to calcium channel blockers between January 2004 and December 2010, at the Adverse Drug Reaction Center of Siriraj hospital, Mahidol University, Bangkok, Thailand were reviewed.Results: From 996,583 prescriptions of calcium channel blockers, forty six patients developed cutaneous adverse effects. Diltiazem was the drug that showed the highest rate of cutaneous reactions per million prescriptions. Maculopapular rash was the most common dermatologic manifestation (41.7%), followed by ankle/pedal edema (18.8%). Three patients (6.2%) developed Stevens-Johnson syndrome due to amlodipine and 1 patient (2.1%) developed toxic epidermal necrolysis due to manidipine. Four patients (8.7%) had renal or cardiovascular involvement.Conclusions: It is important to keep in mind that some patients may develop cutaneous adverse reactions, including severe reactions, from calcium channel blockers.